Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery

Completed · Phase 4

Conditions studied: Bariatric Surgery Candidate

In brief

This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.

Key facts

Study ID

NCT03424239

Run by

Massachusetts General Hospital

People needed

6

Starts

2018-08-01

Expected to finish

2020-01-01

Last updated by the study team

2021-04-29

Who can join

Age: 25 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men must be age ≥ 50
• Women must be age ≥ 25 and postmenopausal
• Planning to receive RYGB or SG surgery

You may not qualify if…

• Age < 25
• Prior bariatric surgery
• Weight ≥ 400 lbs
• Liver or renal disease
• Hypercalcemia, hypocalcemia, or hypomagnesemia
• Serum 25-hydroxyvitamin D < 20 ng/mL
• History of bone-modifying disorders
• Use of bone-active medications
• Known sensitivity to bisphosphonates
• Extensive dental work involving extraction or dental implant within the past 2 months or planned in the upcoming 6 months

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.